A 24-Week Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rosiglitazone When Administered to Pediatric Patients with Type 2 Diabetes Mellitus

Grants and Contracts Details

StatusFinished
Effective start/end date11/1/008/31/02

Funding

  • Smith Kline Beecham: $2,431.00